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The purpose of this study was to examine the use of ultrasound (US)-guided core biopsy of axillary nodes in patients with operable
breast cancer. The ipsilateral axillae of 187 patients with suspected primary operable breast cancer were scanned. Nodes were
classified based on their shape and cortical morphology. Abnormal nodes underwent US-guided core biopsy/fine needle aspiration
(FNA), and the results correlated with subsequent axillary surgery. The nodes were identified on US in 103 of 166 axillae of patients
with confirmed invasive carcinoma. In total, 54 (52%) met the criteria for biopsy: 48 core biopsies (26 malignant, 20 benign node, two
normal) and six FNA were performed. On subsequent definitive histological examination, 64 of 166 (39%) had axillary metastases. Of
the 64 patients with involved nodes at surgery, preoperative US identified nodes in 46 patients (72%), of which 35 (55%) met the
criteria for biopsy and 27 (42%) of these were diagnosed preoperatively by US-guided biopsy. In conclusion, US can identify abnormal
nodes in patients presenting with primary operable breast cancer. In all, 65% of these nodes are malignant and this can often be
confirmed with US-guided core biopsy.
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The primary prognostic discriminant in patients presenting with
breast cancer is lymph node status (Fisher et al, 1983).
Traditionally, axillary dissection at the time of mastectomy or
breast conservation surgery is the method for obtaining this
information regarding the histological nodal status of the patient.
Axillary dissection is commonly associated with morbidity (Ivens
et al, 1992; Duff et al, 2001), and patients who are node negative
derive no benefit from it, hence the recent interest in less invasive
staging procedures such as sentinel node biopsy and axillary node
sampling. The aim of imaging would be to identify patients with
nodal metastases for whom axillary node clearance would be
appropriate. Other patients at low risk of nodal metastases would
be selected for either sampling or sentinel node biopsy.
Existing nonsurgical techniques for preoperative axillary staging
include clinical examination, ultrasonography (US), colour Dop-
pler, scintimammography, high-resolution computed tomography
(HRCT), dynamic contrast enhanced magnetic resonance imaging
(MRI) and positron emission tomography (PET). The range of
sensitivity and specificity quoted in the literature for these
techniques is such that the clinical management of the axilla
cannot be modified for individual patients based upon these test
results. US-guided fine needle aspiration (FNA) has been able to
identify 36 – 63% of node-positive patients preoperatively (Bon-
nema et al, 1997; De Kanter et al, 1999). Image-guided core biopsy
has a higher sensitivity than FNA for assessing breast lesions
(Britton and McCann, 1999), and therefore it would be anticipated
that a similar improvement in sensitivity would be observed in US-
guided core biopsy of the axilla.
The purpose of this study was to examine the usefulness of
ultrasound (US)-guided core biopsy of abnormal axillary nodes in
patients presenting with primary operable breast cancer to enable
level 3 clearance of patients with histologically confirmed nodal
metastases. Patients without histologically confirmed nodal
metastases would then benefit from the lower morbidity of
sampling/sentinel node procedures and subsequent radiotherapy,
where preoperative core biopsy results were falsely negative. To
our knowledge, this is the first study to use 14-gauge core biopsy to
obtain axillary node samples in this clinical setting.
MATERIALS AND METHODS
Over a 9-month period between February 2002 and November 2002,
patients who presented with suspected operable, invasive breast
cancer had their ipsilateral axilla scanned routinely. US assessment
of the axilla was carried out using an 8 – 14MHz probe (Esoate,
Technos 447Zi plus) at the same time as a US scan of the suspected
breast malignant lesion. The axillae were carefully scanned with
particular attention to the lower axilla, posterior to where the
pectoralis major muscle crosses the cranial edge of the breast disc, a
common location for the sentinel node (Krag et al,1 9 9 8 ) .
Nodal features assessed were the shape and the morphology of
the cortex. Nodes were categorised as abnormal in shape if the
longitudinal to the transverse axis ratio was less than two. Nodes Received 13 February 2003; revised 15 July 2003; accepted 24 July 2003
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ywere considered as having abnormal morphology if the cortex was
concentrically or eccentrically thickened to more than 2mm. A
US-guided core biopsy using a 14-gauge needle was performed on
abnormal nodes. When more than one abnormal node was
identified in the axilla, the node that looked most abnormal was
biopsied. Whenever possible, an average of two cores was
obtained. When it was technically difficult to perform a core
biopsy due to the proximity of axillary vessels, a US-guided FNA
was carried out. The core biopsy results were categorised as benign
node, malignant node and normal, when no nodal tissue was
identified in the sample. FNA results in our unit are categorised as
insufficient, benign, equivocal, suspicious and malignant.
All the patients who had nodal metastases on core biopsy
underwent level 3 axillary clearance as a primary procedure at the
time of resection of the primary tumour. The lymph node stage
was determined by the number of positive nodes on the histology
of the surgical specimen; lymph node stage 1 if no nodes were
involved, lymph node stage 2 if three or less nodes were involved
and lymph node stage 3 for four or more involved nodes. Those
patients who did not have nodal metastases confirmed histologi-
cally preoperatively underwent axillary node sampling with or
without sentinel node augmentation, depending on the surgical
preference. Those patients who were shown to have axillary nodal
metastases subsequently underwent either radiotherapy if stage 2,
or axillary clearance if stage 3.
The size and grade of the primary tumour were documented. A
note was made of the mode of presentation of the breast cancer,
that is, whether screen detected or symptomatic, and also if the
axillary nodes were clinically palpable or not. At the end of the
study period, all patients having lesions with clinical or imaging
features suspicious of malignancy, but with benign pathology on
core biopsy or surgery, were excluded from the study group.
Patients were excluded if they did not proceed to surgery because
of a variety of reasons, the most common being medical unfitness
for surgery. Patients with definite locally advanced disease were
also excluded, as they would not have immediate breast or axillary
surgery.
RESULTS
Of the 187 patients whose axillae were scanned, 166 with invasive
cancer were included in the study group. The age range was 33 –
81 years (median age 56 years). The tumour types encountered in
our study group were ductal NST in 92 patients (55%), tubular
mixed in 35 (21%), mixed ductal/lobular in 15 (9%), lobular
classical in 10 (6%), tubular in three (2%) and other types in 11
(7%). Of the 166 patients, 10 (6%) had clinically palpable nodes
suspicious of metastatic disease. Eight of the 10 patients with
clinically palpable nodes had metastases. All eight had more than
three involved nodes at surgery. In total, 55 (33%) of the cancers
were screen detected and 111 (67%) presented symptomatically.
Nodes were identified on US in 103 (62%) of 166 axillae scanned.
Of these, 54 (33%) met the criteria for biopsy. In total, 48 core
biopsies and six FNAs were performed. Of the 48 core biopsies, 26
were malignant, 20 were benign nodes and two normal. Of the six
FNAs, one was benign, four inadequate and one suspicious for
malignancy. There were no complications following core biopsy of
the axillary nodes and our technique did not affect the subsequent
axillary surgical procedure.
In total, 64 (39%) of 166 patients had axillary metastases at
surgery. US-guided core biopsy/FNA identified 27 (42%) of 64
node-positive patients preoperatively. Analysis of our false
negative results revealed that in 18 patients nodes were not
visualised, in 11 patients nodes were identified but did not fit our
criteria for biopsy, in seven patients the core biopsy results were
benign and in one patient the FNA sample was insufficient for
diagnosis.
Preoperative US findings and the results of US-guided core
biopsies when correlated with the nodal stage at surgery are as
shown in Figure 1. The detection of abnormal nodes on US biopsy
increased with increasing burden of metastatic disease in the axilla.
In the 20 patients with more than three involved nodes, 18 (90%)
were diagnosed as node positive preoperatively. In contrast, US-
guided biopsy detected only nine (20%) of 44 patients with three or
less involved nodes at surgery.
US had a sensitivity of 55%, a specificity of 82%, a positive
predictive value (PPV) of 74% and a negative predictive value
(NPV) of 65% in identifying nodal metastases. The overall
sensitivity, specificity, PPV and NPV of US-guided biopsy was
42, 100, 100 and 74%, respectively. In our study, the nodal
positivity rates in patients with no nodes, normal nodes and
abnormal nodes seen on US were 29% (18 of 63), 22% (11 of 49)
and 65% (35 of 54), respectively. The size and grade of the invasive
carcinoma influences the incidence of axillary metastases and their
detection preoperatively by US-guided biopsy (Tables 1 and 2). In
Table 1 Correlation of tumour grade and node positivity
Grade of
the tumour
No. of
patients
Node positivity
at surgery
Node positivity
on US biopsy
Grade 1 37 9 (24%) 2 (22%)
Grade 2 64 23 (36%) 4 (17%)
Grade 3 65 32 (49%) 21 (66%)
Study group
n=166  
hist −
n=102
hist +
n=64 
stage 1
n=102
stage 2
n=44
stage3
n=20
US node+
n=57
US node+
n=27
US node+
n=19
US node−
n=45
US node−
n=17
US node−
n=1
USB
n=19
M
n=0
B
n=14
SE
n=5
M
n=9
B
n=6
SE
n=1
M
n=18
B
n=1
SE
n=0
USB
n=16
USB
n=19
no USB
n=38
no USB
n=11
no USB
n=0
Figure 1 Surgical histology and preoperative US core biopsy results.
n¼no. of patients; hist ¼no malignant nodes on surgical histology;
histþ¼malignant nodes on surgical histology; stage 1¼no positive nodes;
stage 2¼1 – 3 positive nodes; stage 3¼4 or more positive nodes; US
nodeþ¼nodes seen on US; US node ¼no nodes seen on US;
USB¼US core biopsy performed; no USB¼US core biopsy not carried
out as nodes did not meet our criteria for biopsy: M¼malignant;
B¼benign; SE¼sampling error.
Table 2 Correlation of invasive cancer size and node positivity
Size of invasive
cancer at
histology (mm)
No. of
patients
Node positivity
at surgery (%)
Node positivity on
US biopsy (%)
o10 17 2 (12%) 1 (50%)
10 – 14 39 10 (26%) 2 (20%)
15 – 19 42 16 (38%) 4 (25%)
20 – 29 45 19 (42%) 10 (53%)
430 23 17 (74%) 10 (59%)
Total no. 166 64 (39%) 27 (42%)
In 17 patients, the primary tumour was multifocal. The sum of the sizes of all invasive
foci was taken as the final measurement.
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ygrade 1 tumours, the likelihood of detecting involved nodes
preoperatively was low (22%) when compared to detection in
grade 3 tumours (66%). When the size of the primary tumour was
less than 15mm, the incidence of metastases was 21% (12 of 56)
and we could only detect 25% (three of 12) of node-positive
patients preoperatively. However, when the size of the primary
tumour was more than 15mm, the incidence of axillary metastases
was 47% (52 of 110) and we could preoperatively detect 46% (24 of
52) of node-positive patients.
DISCUSSION
It is well documented that axillary nodal status is a major
prognostic indicator and a guide to the need for adjuvant therapy.
Traditionally, axillary dissection is performed primarily to obtain
information on the histological nodal status of the patient and
therapeutically to reduce the risk of axillary recurrence. Complete
axillary dissection causes morbidity and patients who are node
negative derive no benefit from it. Our study shows that if nodal
positivity can be determined preoperatively by imaging techniques
and percutaneous biopsy, a group of patients who maximally
benefit from axillary dissection can be identified. A knowledge of
nodal status preoperatively, along with other factors such as
histological grade on core biopsy, may also indicate the need for
postoperative mastectomy flap irradiation, which would influence
the feasibility of immediate reconstruction (O’Rourke et al, 1994).
A preoperative knowledge of node positivity is seen by some as an
indication for neo-adjuvant chemotherapy.
The imaging techniques that have been extensively investigated
to assess the axilla preoperatively are US with a reported sensitivity
of 56 – 72% and a specificity of 70 – 90% (Bruneton et al, 1986; de
Freitas et al, 1991; Vaidya et al, 1996; Feu et al, 1997),
scintimammography with a sensitivity of 67 – 100% and a
specificity of 80 – 90% (Dupont et al, 2001; Lumachi et al, 2001),
CT with a sensitivity of 90% and a specificity of 82% (March et al,
1991; Uematsu et al, 2001) and colour Doppler with a sensitivity of
76% (Yang et al, 2000, 2001). The sensitivity and specificity
achieved using these techniques does not allow a reliable selection
of patients for full axillary clearance or a more minimally invasive
procedure. More recent advances such as dynamic contrast
enhanced MRI has a sensitivity and an NPV of 100% (Yoshimura
et al, 1999; Murray et al, 2002) and 2-[(18) F] fluoro-2-deoxy-D-
glucose-PET has a sensitivity of 82 – 95% and an NPV of 88%
(Greco et al, 2001; Wahl, 2001). These two imaging modalities
may be reliable in predicting the absence of nodal metastases
in women with breast cancer, but these techniques are
not readily available, are expensive and the results need to be
confirmed in large multicentre studies. Although some of the
above techniques are less expensive and have higher sensitivity
than US-guided core biopsy, their PPV is appreciably less than
100%. If surgical management were based on these tests, the
number of women with axillary clearance who did not have nodal
metastases would be higher. Although US core biopsy is much less
sensitive in our hands, the PPV is 100% and this enables our
surgeons to perform axillary clearance selectively as a primary
procedure in a group of patients with proven metastases on core
biopsy.
In many of the studies assessing the role of US in the detection
of malignant nodes, a number of criteria such as size, presence or
absence of nodal hilum, echo texture, shape, focal doubling of the
cortical thickness and cortical morphology were used indepen-
dently or in combination. However, the US study by Vassallo et al
(1992) and a more recent in vitro study using high-resolution CT
by Uematsu et al (2001) have shown that nodal shape, that is, a
longitudinal by transverse axis ratio of less than 2, and abnormal
morphology of the cortex with a thickness of more than 2mm are
the two most reliable criteria in predicting malignancy in vivo.W e
adopted these criteria in our study to identify abnormal nodes and
selectively biopsy them. The ease of assessment of these factors
made it feasible to assess the axilla at the same time as US of the
suspected primary malignancy in the breast.
In order to increase the specificity of preoperative assessment of
the axilla, a number of groups have performed US-guided FNA
(Bonnema et al, 1997; Verbanck et al, 1997; De Kanter et al, 1999;
Krishnamurthy et al, 2002). Bonnema and de Kanter used this
technique to detect axillary metastases in patients with operable
breast cancer and preoperatively identified 63% (39 of 62) and 36%
(31 of 87) of node-positive patients, respectively.
It is well documented that core biopsy of breast lesions is
superior to FNA. We therefore thought it likely that core biopsy
might prove to be superior to FNA in evaluating axillary lymph
nodes. We used core biopsy with a 14-gauge biopsy needle to
obtain axillary node samples. Using this technique to biopsy nodes
that fulfilled our criteria, we could detect 27 of 64 (42%) of node-
positive patients preoperatively. In all, 65% of all ultrasonogra-
phically abnormal nodes in our study had axillary metastases.
However, 29% of patients with no identifiable nodes and 22%
with normal nodes also had metastases. The similarity of
nodal positivity in the normal and no node seen group suggests
that lowering the threshold for biopsy of nodes seen would
not be that effective in increasing the preoperative diagnosis of
axillary metastases. US and core biopsy of abnormal nodes
was reliable in detecting nodal metastases when the axillary
burden of disease was high (four or more involved nodes).
However, this technique was not sensitive in detecting axillary
metastases when the disease burden was low (three or fewer nodes
involved). The experience of our unit and others shows that a
sampling procedure combined with axillary radiotherapy for
patients with one to three positive nodes provides excellent long-
term disease control with minimal morbidity (Lambah et al, 2001;
Rampaul et al, in press). Patients who benefit most from axillary
clearance are those with four or more positive nodes. This study
demonstrates how these patients can be identified preoperatively.
In our experience, there was increasing incidence of axillary
metastases and their detection by US-guided biopsy with increas-
ing size and grade of the invasive cancer. Our results using core
biopsies are similar to previous studies using US-guided FNA. It is
unclear whether FNA or core is best and how many passes are
required for optimal results. There have been reports that gamma
probe and US-guided FNA might be a potentially useful method
for preoperative detection of sentinel node metastases (Motomura
et al, 2001). Perhaps the sensitivity of US-guided biopsy could be
improved by increasing the number of passes and samples
obtained from the visualised abnormal nodes, and by preferentially
imaging the sentinel node by dual scanning with a gamma probe
and high-frequency US.
In conclusion, US can identify abnormal lymph nodes in
patients presenting with primary operable breast cancer. In total,
65% of these nodes are malignant and this can often be confirmed
by US-guided core biopsy. In all, 42% of all node-positive patients
were correctly identified preoperatively.
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